tms1 Antibody

What is TMS1 protein and why is it important in research?

TMS1 (also known as ASC/PYCARD) is a 21.4 kDa protein that functions as a key mediator in both apoptosis and inflammation processes. It plays a critical role in innate immune response by acting as an integral adapter in the assembly of various inflammasomes (NLRP1, NLRP2, NLRP3, NLRP6, AIM2, and IFI16) . These inflammasomes recruit and activate caspase-1, leading to the processing and secretion of pro-inflammatory cytokines including IL-1β and IL-18. Additionally, TMS1 is involved in promoting caspase-mediated apoptosis, particularly through caspase-8 and caspase-9 in a cell type-specific manner . The gene's hypermethylation in various cancers makes it an important research target for understanding tumor development and potential therapeutic approaches.

What types of TMS1 antibodies are available for research applications?

Researchers can choose between monoclonal and polyclonal antibodies for TMS1 detection. Monoclonal antibodies like clone OTI1A2 and OTI3E9 offer high specificity and consistent lot-to-lot reproducibility . These are developed against recombinant human TMS1 protein produced in E. coli. Polyclonal antibodies provide broader epitope recognition, potentially increasing detection sensitivity particularly in applications where protein conformation might be altered . Both IgG1 isotype (mouse monoclonal) and rabbit polyclonal IgG formats are available, with various formulations including BSA-free options for applications that might be sensitive to carrier proteins .

What are the major research applications for TMS1 antibodies?

TMS1 antibodies are validated for multiple research applications including:

These antibodies have been validated across various human tissues including liver, lung, skeletal muscle, and spleen, as well as in cell lines such as THP-1, HepG2, HeLa, and Jurkat . The diversity of applications makes these antibodies versatile tools for investigating TMS1's role in normal physiology and disease states.

How should I optimize Western blot protocols for TMS1 detection?

For optimal Western blot detection of TMS1, begin with protein extraction using RIPA buffer containing protease inhibitors to prevent degradation of the target protein. Load 25-35 μg of total protein per lane as demonstrated in validation studies across multiple cell lines (HepG2, HeLa, Jurkat, etc.) . Use a 12-15% gel for optimal resolution of the 22 kDa TMS1 protein. The recommended antibody dilution range is 1:500-1:2000, with overnight incubation at 4°C typically yielding the best results. When optimizing, consider using THP-1 cell lysates as a positive control since they consistently show strong TMS1 expression. If investigating tissue-specific expression patterns, note that detection sensitivity may vary across different tissue types, requiring adjustment of exposure times and antibody concentrations.

What are the critical considerations for immunohistochemical detection of TMS1?

When performing immunohistochemistry with TMS1 antibodies, antigen retrieval is crucial. For paraffin-embedded sections, heat-induced epitope retrieval using 10mM citric buffer (pH 6.0) at 100°C for 10 minutes is recommended . Block with 5-10% normal serum from the same species as the secondary antibody for at least 1 hour to reduce background staining. The optimal antibody dilution for IHC is approximately 1:150, with overnight incubation at 4°C. When interpreting results, note that TMS1 shows moderate cytoplasmic positivity in specific cell types such as Kupffer cells in liver tissue . For multiplex staining, carefully select antibodies raised in different host species to avoid cross-reactivity. Temperature control during incubation steps is essential for reproducible results, as is the inclusion of both positive and negative controls in each experimental run.

How can I validate the specificity of TMS1 antibody in my experimental system?

Validating TMS1 antibody specificity requires a multi-faceted approach. First, perform Western blot analysis to confirm detection of a single band at the expected molecular weight (~22 kDa) in positive control samples like THP-1 cells . Compare results using at least two independent antibodies targeting different epitopes of TMS1, such as OTI1A2 and OTI3E9 clones . For definitive validation, include a negative control using cells where TMS1 expression is knocked down via siRNA or CRISPR-Cas9. Flow cytometry comparing cells transfected with TMS1 overexpression plasmid versus empty vector control provides another validation method, as demonstrated with HEK293T cells . For tissue samples, compare staining patterns across multiple antibodies to confirm consistent localization patterns, as shown in orthogonal validation studies using human liver, lung, and spleen tissues .

How can TMS1 antibodies be used to study inflammasome assembly and activation?

TMS1 antibodies are valuable tools for investigating inflammasome assembly dynamics. For co-immunoprecipitation experiments, use 1-2 μg of TMS1 antibody per 500 μg of total protein lysate to pull down inflammasome complexes, followed by Western blot analysis for associated proteins like NLRP3, caspase-1, or IL-1β. For visualizing inflammasome specks, perform immunofluorescence microscopy using TMS1 antibodies at 1:100-1:200 dilution, counterstained with DAPI. Confocal microscopy can reveal the characteristic punctate structures formed during inflammasome activation. Flow cytometry using TMS1 antibodies can quantify inflammasome formation across cell populations following stimulation with activators like ATP, nigericin, or particulate matter. Time-course experiments combining these techniques can provide insights into the kinetics of inflammasome assembly and activation, revealing how TMS1 transitions from a diffuse cytoplasmic distribution to discrete specks during the inflammatory response.

What approaches can be used to study TMS1 methylation status in cancer research?

To investigate TMS1 methylation in cancer contexts, researchers can combine epigenetic analysis with protein detection. Begin with methylation-specific PCR or bisulfite sequencing to assess the methylation status of the TMS1 promoter region. Then correlate these findings with protein expression levels using Western blot and immunohistochemistry with TMS1 antibodies. In tissue microarrays from cancer samples, use TMS1 antibodies at 1:150 dilution to assess protein expression patterns across tumor stages . For functional studies, treat cancer cell lines with demethylating agents like 5-aza-2'-deoxycytidine and monitor changes in TMS1 expression using Western blot and qRT-PCR. Chromatin immunoprecipitation (ChIP) assays can further characterize the epigenetic regulation of TMS1. This multi-modal approach allows researchers to establish relationships between epigenetic silencing and protein expression in cancer progression.

How can I use TMS1 antibodies to investigate the protein's role in apoptotic pathways?

To study TMS1's function in apoptotic pathways, combine TMS1 antibody-based detection with apoptosis assays. First, induce apoptosis using standard methods (staurosporine, TNF-α/cycloheximide, or UV radiation), then perform subcellular fractionation followed by Western blot with TMS1 antibodies to track translocation between compartments. Co-immunostaining for TMS1 (1:100-1:200) and apoptotic markers like activated caspase-3 can reveal temporal relationships during apoptosis progression. For mechanistic studies, perform co-immunoprecipitation with TMS1 antibodies followed by Western blotting for interaction partners like caspase-8, BID, or BAX . Time-lapse confocal microscopy with fluorescently-tagged TMS1 antibodies (when available) can visualize real-time dynamics of TMS1 redistribution during apoptosis. These approaches collectively illuminate TMS1's contributions to both mitochondrial-dependent and independent apoptotic pathways.

What are common technical issues with TMS1 detection and how can they be resolved?

When troubleshooting TMS1 detection, researchers frequently encounter several challenges. For weak Western blot signals, increase protein loading to 35-50 μg, extend primary antibody incubation to overnight at 4°C, and optimize transfer conditions for this relatively small protein (22 kDa) . Non-specific bands may appear due to protein degradation; prevent this by adding protease inhibitors to lysis buffers and keeping samples cold throughout processing. For immunohistochemistry, background staining can be minimized by extending blocking time to 2 hours and performing more thorough washing steps. If tissue-specific detection is variable, optimize antigen retrieval conditions—for formalin-fixed samples, citrate buffer at pH 6.0 is recommended, but some tissues may require alternative buffers like EDTA (pH 8.0-9.0) . For flow cytometry applications with inconsistent results, verify antibody compatibility with fixation/permeabilization protocols and optimize concentrations empirically for each cell type.

How should I interpret conflicting TMS1 expression data across different detection methods?

When confronted with discrepancies in TMS1 expression between methods (e.g., Western blot vs. IHC), several considerations can guide interpretation. First, recognize that each technique detects proteins under different conditions: Western blot after denaturation, while IHC may detect native conformations. Compare results against appropriate positive controls like THP-1 cells for Western blotting . Post-translational modifications may affect epitope accessibility; phosphorylation and ubiquitination of TMS1 can alter antibody binding . Consider potential splice variants or proteolytic processing affecting antibody recognition sites. Quantify expression levels relative to housekeeping controls and compare ratios rather than absolute values. For definitive resolution, employ orthogonal validation using multiple antibodies targeting different epitopes . When publishing results, transparently report these methodological considerations and always include detailed experimental procedures to facilitate interpretation by the scientific community.

How can I distinguish between specific TMS1 staining and background in complex tissue samples?

Distinguishing specific TMS1 staining from background in complex tissues requires rigorous controls and optimization. Include isotype control antibodies matched to your primary antibody (e.g., mouse IgG1 for OTI1A2 clone) to identify non-specific binding. Perform peptide competition assays by pre-incubating the antibody with recombinant TMS1 protein—specific signals should be significantly reduced. Compare staining patterns across serial sections using independent antibodies targeting different TMS1 epitopes; true signals should show consistent localization patterns, as demonstrated in comparative studies of human liver and spleen . In multiplex immunofluorescence, include single-stain controls to identify spectral overlap. For tissues with high autofluorescence (like brain or lung), employ specific autofluorescence quenching protocols. When analyzing Kupffer cells in liver samples, use co-staining with macrophage markers to confirm cell-type specificity of TMS1 expression, as these cells typically show moderate cytoplasmic positivity .

How can TMS1 antibodies be used in studies of inflammasome-related diseases?

TMS1 antibodies enable detailed investigation of inflammasome dysregulation in diseases like inflammatory bowel disease, neurodegenerative disorders, and metabolic syndrome. For patient-derived samples, use immunohistochemistry with TMS1 antibodies (1:150 dilution) to compare expression levels and distribution patterns between healthy and diseased tissues . In mouse models of inflammasome-related diseases, perform dual immunofluorescence with TMS1 (1:100) and disease-specific markers to identify affected cell populations. Laser capture microdissection combined with Western blot analysis can isolate and examine TMS1 expression in specific tissue microenvironments. For clinical correlation studies, quantify TMS1-positive inflammasome specks in patient samples and analyze their relationship with disease severity scores and biomarkers of inflammation. These approaches can reveal how TMS1-dependent inflammasome activation contributes to pathogenesis and potentially identify new therapeutic targets for inflammatory conditions.

What are the considerations for using TMS1 antibodies in multiplex immunofluorescence studies?

Multiplex immunofluorescence with TMS1 antibodies requires careful experimental design. Begin by selecting antibodies raised in different host species (mouse monoclonal and rabbit polyclonal are both available) to allow simultaneous staining without cross-reactivity. When combining with other inflammasome components, consider the following validated combinations: TMS1 (1:100) with NLRP3 (1:50-1:100) and caspase-1 (1:100-1:200). For optimal spectral separation, select fluorophores with minimal overlap—Alexa Fluor 488 for TMS1, Alexa Fluor 568 for NLRP3, and Alexa Fluor 647 for caspase-1 work well together. Perform sequential rather than simultaneous antibody incubations if cross-reactivity is observed. Tissue autofluorescence can be mitigated using specialized quenching reagents or Sudan Black B. Always include single-stained controls for accurate spectral unmixing, particularly when using confocal or super-resolution microscopy to visualize inflammasome assembly structures.

How should researchers approach the use of TMS1 antibodies in live-cell imaging studies?

Live-cell imaging with TMS1 antibodies presents unique challenges that require specialized approaches. Consider using cell-permeable fluorescently conjugated antibody fragments (Fab fragments) of anti-TMS1 antibodies, which can be generated through enzymatic digestion of whole IgG molecules. For visualizing inflammasome formation dynamics, transfect cells with fluorescently tagged TMS1 constructs (GFP-TMS1 or RFP-TMS1) and validate expression patterns using fixed-cell immunofluorescence with TMS1 antibodies. Alternative approaches include using cell lines with endogenous TMS1 tagged with fluorescent proteins via CRISPR-Cas9 knock-in strategies. For temporal studies of inflammasome activation, combine TMS1 visualization with real-time caspase-1 activity probes (FLICA reagents) or calcium indicators. Maintain physiological conditions during imaging (37°C, 5% CO2, appropriate humidity) and minimize phototoxicity by using sensitive cameras and reducing exposure times. These approaches enable dynamic visualization of TMS1's role in inflammasome assembly with temporal and spatial resolution not achievable in fixed samples.